Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Hims & Hers’ ad takes the issue head-on ... But due to the soaring demand for these weight loss drugs, it’s now a mainstream phenomenon. Semaglutide has been on the market for 20 years, but it was ...